In the short term, organizations can better control their costs and provide consistent quality of care.  In the long term, they can provide greater quality and control their costs through compliance assessment and continuously improving the guidelines.  For pharmaceutical companies and care research organizations (CRO) we support clinical trial protocols and results analysis.

By integrating medical data and medical knowledge engines, we created a revolutionary technology that enables:

1.  Clinically meaningful time-oriented pattern detection, and
2. Application of procedural clinical knowledge, according to guidelines and protocols.

 The Challenge:

With Healthcare costs outstripping the GDP according to the OECD, and with 25% of the population, i.e. chronic-care patients consuming 80% of the Healthcare resources, controlling costs is the number one item for all CDOs. At the same time, Healthcare data is exploding but not properly utilized. CDOs try to control this by implementing clinical guidelines, but often, the problem is that CDOs do not follow their own guidelines due to a lack of tools.  As a result, there is inconsistent quality of care and spiraling costs. Moreover, improving the guidelines does not necessarily improve the quality of care or cost control, as there are no means of monitoring them. Most caregivers do not have the level of Clinical Decision Support (CDS) they need to leverage clinical data. This presents a serious and costly problem as CDS is the single most important Computer-Based Patient Records (CPR) capability to assist in the avoidance of medical errors.  

Since the Institute of Medicine's 1999 report "To Err Is Human" identified the need to reduce medical errors while at the same time improve the quality and reliability of healthcare that is delivered, clinical automation systems have played a crucial role in achieving these dual goals. Much of this potential is based on the incorporation of a clinical decision support capability into these complex CPR systems.  This has been a major driver of the surge of investment in CDS over the last years.

The industry is fragmented with small competitors providing only partial, piecemeal applications to the guideline compliance problem. Several competitors offer analytical tools and a few even analyze clinical data over time. But, CDOs and pharmaceutical companies need a comprehensive solution to the guideline compliance problem.